苦参制剂联合扶正化瘀胶囊对乙型肝炎肝硬化患者肝血流动力学及纤维化指标的影响

摘要

OBJECTIVE:To investigate the effects and safety of Sophoraflavescens preparation combined with Fuzheng huayu capsule on hepatic hemodynamics and fibrosis indexes in patients with hepatitis B liver cirrhosis.METHODS:One hundred and two patients diagnosed as hepatitis B liver cirrhosis in our hospital during Feb.2013-Jun.2014 were divided into combination group and control group according to random number table,with 51 cases in each group.Control group was treated with Adefovir dipivoxil capsules 10 mg,po,qd;combination group was additionally given Fuzheng huayu capsules 1.5 g,po,tid+Sophora flavescens preparation (Matrine glucose injection 250 mL,ivgtt,qd,in the first 3 months,oxymatrine capsules 200 mg,po,tid,after 3 months) on the basis of control group.Both groups were treated for 12 months.The levels of HBV-DNA,liver function indexes (AST,ALT,TBIL),portal hemodynamic indexes [main portal vein inner diameter (D),mean blood flow velocity (Ⅴ)] and liver fibrosis indexes [laminin protein (LN),hyaluronic acid (HA),type Ⅳ collagen (Ⅳ-C)] were observed in 2 groups before and after treatment.The negative conversion rate of HBV-DNA and incidence of ADR were recorded.RESULTS:Three cases lost to follow up,and a total of 48 effective cases were included in control group;5 cases lost to follow up,and a total of 46 effective cases were included in combination group.Before treatment,there was no statistical significance in HBV-DNA levels,liver function indexes (AST,ALT,TBIL),liver fibrosis indexes (LN,HA,Ⅳ-C) and portal vein hemodynamic indexes (D,V) between 2 groups (P＞0.05).After treatment,above indexes of 2 groups were decreased significantly,and the combination group was significantly lower than the control group,with statistical significance (P＜0.05).The negative conversion rate of HBV-DNA in combination group was 93.5％,which was significantly higher than 79.2％ of control group,with statistical significance (P＜0.05).There was no statistical significance in the incidence of ADR between 2 groups (P＞0.05).CONCLUSIONS:Sophora flavescens preparation combined with Fuzheng huayu capsules can promote the recovery of liver function,regulate liver hemodynamics and alleviate hepatic fibrosis in patients with hepatitis B liver cirrhosis with good safety.%目的:探讨苦参制剂联合扶正化瘀胶囊对乙型肝炎(以下简称“乙肝”)肝硬化患者肝血流动力学、纤维化指标的影响及安全性.方法:选取2013年2月-2014年6月我院确诊为乙肝肝硬化患者102例,按随机数字表法分为联合组和对照组,各51例.对照组患者给予阿德福韦酯胶囊10 mg,po,qd;联合组患者在对照组基础上加用扶正化瘀胶囊1.5 g,po,tid+苦参制剂(初始3个月给予苦参碱葡萄糖注射液250 mL,ivgtt,qd,3个月给予苦参素胶囊200mg,po,tid).两组患者均持续治疗12个月.观察两组患者治疗前后乙肝病毒脱氧核糖核酸(HBV-DNA)、肝功能指标[天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、总胆红素(TBIL)]、门静脉血流动力学指标[门静脉主干内径(D)、平均血流速度(Ⅴ)]、肝纤维化指标[层粘连蛋白(LN)、透明质酸(HA)、Ⅳ型胶原(Ⅳ-C)]水平,并记录其HBV-DNA阴转率及不良反应发生率.结果:对照组脱落3例,共48例有效病例入组;联合组脱落5例,共46例有效病例入组.治疗前,两组患者HBV-DNA、肝功能指标(AST、ALT、TBIL)、肝纤维化指标(LN、HA、Ⅳ-C)及门静脉血流动力学指标(D、V)水平比较,差异均无统计学意义(P＞0.05);治疗后,两组患者上述指标水平均显著降低,且联合组显著低于对照组,差异均有统计学意义(P＜0.05).联合组患者HBV-DNA阴转率为93.5％,显著高于对照组的79.2％,差异有统计学意义(P＜0.05).两组患者不良反应发生率比较,差异无统计学意义(P＞0.05).结论:苦参制剂联合扶正化瘀胶囊能促进乙肝肝硬化患者肝功能恢复、调节肝区血流动力学状态、缓解纤维化,且安全性较好.